PTYLTD
    • Free Reports
    • Videos
  • Pricing
  • About us
  • Contact us
  • Login | Sign up
PTYLTD

Free Reports

Videos

Pricing

About us

Contact us

  • Home
  • Insights into ASX Stocks
  • By Topic

By Topic

Korvest (ASX: KOV)

How much higher can Korvest (ASX: KOV) share price go after the recent breakout?

Feb 4, 2026
Proactive Equities Team

Korvest Ltd (ASX: KOV) is a South Australian industrial manufacturer specialising in cable and pipe support systems and corrosion protection services, with earnings linked to infrastructure, resources, energy and industrial activity, as well as ongoing maintenance demand.

Aristocrat Leisure (ASX: ALL)

Aristocrat Leisure (ASX: ALL): Strong Results Spark Re-Rating—But Can Growth Continue?

May 20, 2026
Proactive Equities Team

Aristocrat Leisure is a global gaming company delivering strong HY26 earnings growth and driving a share price re-rating, supported by buybacks and land-based strength, while investors remain cautious about whether digital segment growth can sustain long-term momentum.

DXN

From 2 Cents to 14 Cents: DXN Delivers One of the ASX's Biggest Rallies of 2026

Jun 10, 2026
Proactive Equities Team

DXN's share price surged from 2 cents to 14 cents in 2026 after winning major AI and telecommunications infrastructure contracts. The modular data centre specialist is expanding globally, with investors betting on strong growth from AI, cloud, and digital infrastructure markets.

BrainChip Holdings (ASX: BRN)

Has BrainChip Holdings (ASX: BRN) Broken Its Downtrend and Started Building a New Support Base?

Jun 22, 2026
Proactive Equities Team

BrainChip develops low-power edge AI chips via its Akida platform. Recent momentum reflects licensing and product roadmap optimism, but weak revenue, losses, and dilution remain risks. Technically, BRN has broken its downtrend and is testing support near 0.16 to 0.17.

4DMedical (ASX: 4DX)

4DMedical (ASX: 4DX) Pulls Back After Breakout Rally

Jun 26, 2026
Proactive Equities Team

4DMedical slipped to A$4.57 after its breakout rally, as traders took profit near A$5.00. Momentum remains constructive, but holding A$4.25–A$4.50 is crucial while CT expansion, acquisitions and SaaS growth support the broader story.

Island Pharmaceuticals (ASX: ILA)

Island Pharmaceuticals (ASX: ILA) Breaks Its Downtrend as Galidesivir News Puts It Back in Play

Jul 8, 2026
Proactive Equities Team

Island Pharmaceuticals has regained market attention after breaking a long-term downtrend, supported by Galidesivir developments and strong trading momentum. Recent updates across biodefence, manufacturing, and intellectual property have improved sentiment, although confirmation above key resistance remains important

...

 

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Home
Pricing
Contact Us
About Us

Resources

ASX Insights
Investing Basics

Links

Privacy Policy
Terms and Conditions
Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

1...111213...42
Page 12 of 42